Genmab A (GMAB) Invested Capital (2022 - 2026)

Genmab A (GMAB) has reported Invested Capital for 5 consecutive years, with $11.1 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Invested Capital changed N/A year-over-year to $11.1 billion; the trailing twelve-month figure through Jun 2026 stood at $11.1 billion (changed N/A YoY), and the FY2025 full-year result was $11.1 billion, up 217.26% from the prior year.
• Invested Capital rose to $11.1 billion in Q2 2026 per GMAB's latest filing, from $10.6 billion in the prior quarter.
• Across five years, Invested Capital topped out at $11.1 billion in Q4 2025 and bottomed at $2.7 billion in Q4 2022.
• Historically, Invested Capital has averaged $7.0 billion across 5 years, with a median of $7.1 billion in 2026.
• The sharpest annual moves came in 2023 and 2025: Invested Capital gained 13.38% in 2023, then soared 217.26% in 2025.
• Over 5 years, Invested Capital stood at $2.7 billion in 2022, then grew by 13.38% to $3.1 billion in 2023, then climbed by 14.58% to $3.5 billion in 2024, then jumped by 217.26% to $11.1 billion in 2025, then slipped by 0.26% to $11.1 billion in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $11.1 billion, $10.6 billion, and $11.1 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.